Insulin is not a controlled substance and has no DEA schedule. Unlike medications such as opioids or benzodiazepines that are classified into Schedules I through V under the Controlled Substances Act, insulin sits entirely outside that framework. Its regulatory classification has changed over the years, though, and the rules around purchasing it vary more than most people expect.
Why Insulin Has No Schedule
The DEA scheduling system exists to regulate drugs with potential for abuse or dependence. Schedule I includes substances with no accepted medical use and high abuse potential, while Schedules II through V represent decreasing levels of risk. Insulin, a hormone the body naturally produces to regulate blood sugar, has no abuse potential and no psychoactive effects. There is no reason to restrict it through the scheduling system, so it has never been assigned a schedule.
What has changed is insulin’s broader regulatory category. Until March 23, 2020, insulin was regulated as a drug under the Federal Food, Drug, and Cosmetic Act. On that date, the FDA transitioned insulin to a biological product under the Public Health Service Act. This reclassification didn’t affect scheduling (insulin still has none) but it opened the door for biosimilar and interchangeable versions of insulin to enter the market, which is significant for competition and pricing.
Prescription vs. Over-the-Counter Insulin
Even without a DEA schedule, most insulin products in the United States require a prescription. Modern insulin analogs, the rapid-acting and long-acting formulations that most people with diabetes use today, are classified as “legend drugs,” meaning a licensed prescriber must authorize them.
However, certain older insulin formulations were grandfathered in before modern prescription requirements took effect. These older human insulins, including regular human insulin and NPH insulin, can technically be sold without a prescription in many states. The practical experience of buying them varies by state and even by pharmacy, since individual stores may have their own policies requiring a prescription regardless of what state law allows.
Insulin syringes add another layer of complexity. Some states, like North Carolina, explicitly allow pharmacists to sell syringes to anyone without a prescription. Others, like Tennessee and Virginia, require proof of medical need or a documented legitimate purpose before dispensing syringes without a prescription. A pharmacist in Tennessee might interpret that as needing an insulin prescription on file at the pharmacy before selling syringes over the counter.
Emergency Refill Laws
Because insulin is life-sustaining and gaps in supply can be dangerous, several states have passed laws allowing pharmacists to dispense insulin in emergencies without a current prescription. Texas, for example, enacted Kevin’s Law in 2021, which authorizes a pharmacist to dispense a 30-day emergency refill of insulin along with related equipment and supplies when the pharmacist cannot reach the patient’s prescriber for authorization. Similar laws exist in other states, though the specific rules around quantity and documentation differ.
Biosimilar Insulin and Pharmacy Substitution
The 2020 reclassification of insulin as a biological product had a practical consequence: it enabled the FDA to approve biosimilar insulins. In July 2021, the first interchangeable biosimilar insulin reached the market. This product, a version of long-acting insulin glargine, is both biosimilar to and interchangeable with the brand-name reference product. The “interchangeable” designation is important because it gives pharmacists the ability to substitute the biosimilar at the pharmacy counter without calling the prescriber first, unless the prescription specifically states that the brand-name version is required. State laws govern exactly how this substitution works, so the process can differ depending on where you fill your prescription.
Cost Caps for Medicare Patients
Starting January 1, 2023, the Inflation Reduction Act capped out-of-pocket insulin costs at $35 per month per covered insulin product for people enrolled in Medicare prescription drug plans. Part D deductibles no longer apply to covered insulin products either. As of July 1, 2023, the same $35 monthly cap extends to Medicare Part B and Medicare Advantage beneficiaries who use insulin with a traditional pump. This applies to roughly 4 million seniors and other Medicare beneficiaries with diabetes. For people with private insurance or no insurance, the $35 cap does not apply, though several major insulin manufacturers have voluntarily introduced their own price caps or discount programs.
What This Means in Practice
If you’re asking whether insulin is a controlled substance because you’re worried about difficulty obtaining it, the short answer is that the barriers to getting insulin are not about scheduling. They’re about prescription requirements, insurance coverage, and cost. Most modern insulins need a prescription, but they won’t trigger the extra scrutiny, ID checks, or refill limits that come with scheduled medications. Your pharmacist won’t need to check a prescription drug monitoring database, and there are no limits on how many refills your doctor can authorize at once.
If you’re in a situation where you need insulin urgently and your prescription has lapsed, check whether your state has an emergency dispensing law. Many pharmacists can provide a short-term supply to bridge the gap while you get a new prescription.